Relay Therapeutics Inc’s recent filing unveils that its insider Rahmer Peter unloaded Company’s shares for reported $32217.0 on Apr 30 ’25. In the deal valued at $3.00 per share,10,739 shares were sold. As a result of this transaction, Rahmer Peter now holds 390,081 shares worth roughly $1.28 million.
Then, Rahmer Peter sold 1,364 shares, generating $4,324 in total proceeds. Upon selling the shares at $3.17, the insider now owns 400,820 shares.
Before that, Catinazzo Thomas sold 12,943 shares. Relay Therapeutics Inc shares valued at $38,829 were divested by the Chief Financial Officer at a price of $3.00 per share. As a result of the transaction, Catinazzo Thomas now holds 355,376 shares, worth roughly $1.16 million.
Wells Fargo initiated its Relay Therapeutics Inc [RLAY] rating to an Equal weight in a research note published on April 17, 2025; the price target was $4. A number of analysts have revised their coverage, including Jefferies’s analysts, who increased its forecast for the stock in early September from “a Hold” to “a Buy”. Oppenheimer revised its rating on September 10, 2024. It rated RLAY as “a Perform” which previously was an “an Outperform”.
Price Performance Review of RLAY
On Monday, Relay Therapeutics Inc [NASDAQ:RLAY] saw its stock jump 1.55% to $3.27. Over the last five days, the stock has lost -2.68%. Relay Therapeutics Inc shares have fallen nearly -20.63% since the year began. Nevertheless, the stocks have fallen -58.29% over the past one year. While a 52-week high of $10.72 was reached on 01/10/25, a 52-week low of $1.77 was recorded on 04/07/25.
Levels Of Support And Resistance For RLAY Stock
The 24-hour chart illustrates a support level at 3.14, which if violated will result in even more drops to 3.02. On the upside, there is a resistance level at 3.35. A further resistance level may holdings at 3.43.
